The company held a restricted manufacturing authorisation until 30 June 2020. Based on the evaluation of the company's CAPA plan the manufacturing authorisation cannot be prolonged. Major systemic deficiencies in the areas of supplier qualification, change management, deviation management, qualification of equipment, validation of computerised systems and good documentation practice could not be resolved. Action taken/proposed by the NCA: Revocation of the manufacturing authorisation No. 482723 in Full Withdrawal, of current valid GMP certificate No. 482723-0003 The company held a restricted GMP certificate valid until 30 June 2020. A new certificate will not be issued.
Inspection Record
Lupuca Pharma GmbH — EU GMP NCR (EudraGMDP) Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
1Documentation and records
About this record
Extracted automatically from the document EMA (Europe) published on 2020-06-30. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
